Scilex Holding (SCLX) Cash & Equivalents (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Cash & Equivalents of $144.9 million for Q1 2026, up 2397.81% year-over-year from $5.8 million in Q1 2025, and up 2823.77% on a QoQ basis from $5.0 million in Q4 2025.
Scilex Holding (SCLX) Cash & Equivalents (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Cash & Equivalents for 7 consecutive years, with $144.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 2397.81% year-over-year to $144.9 million; the TTM figure through Mar 2026 stood at $144.9 million (up 2397.81% YoY), while the FY2025 annual figure was $5.0 million, up 51.44% from the prior year.
- Cash & Equivalents came in at $144.9 million for Q1 2026 at Scilex Holding, up from $5.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $144.9 million in Q1 2026, with the low at $34961.0 in Q3 2022.
- Average Cash & Equivalents over 5 years is $13.0 million, with a median of $3.3 million recorded in 2024.
- Across the five-year window, Cash & Equivalents soared 9613.84% in 2023 and tumbled 96.15% in 2024, its largest moves.
- Year by year, Cash & Equivalents stood at $2.2 million in 2022, then surged by 79.53% to $3.9 million in 2023, then retreated by 16.55% to $3.3 million in 2024, then soared by 51.44% to $5.0 million in 2025, then soared by 2823.77% to $144.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $144.9 million, $5.0 million, and $900000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 21.69 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.56 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 144.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144.87 Mn |
| Dec 31, 2025 | 4.96 Mn |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 5.80 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 34.12 Mn |
| Mar 31, 2023 | 5.10 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 34,961.00 |
| Jun 30, 2022 | 351,272.00 |
| Mar 31, 2022 | 127,440.00 |
| Dec 31, 2021 | 4.34 Mn |
| Sep 30, 2021 | 115,642.00 |
| Jun 30, 2021 | 257,621.00 |